secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001104659-24-129367
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA posts FY2024 revenue of $3.4M, net loss $7.1M; announces restructuring and leadership changes
--------------------------------------------------------------------------------

- Q4 revenue $813K (up vs $780K YoY); FY revenue $3.4M vs $13.4M; net loss Q4 $3.3M ($0.32/sh), FY $7.1M ($1.82/sh).
- Pursuing divestiture of CertainT platform; targeting 15% opex reduction vs FY2024, expected by Q2 FY2025.
- Judith Murrah promoted to President (salary increased to $400K); Clay Shorrock named President of LineaRx subsidiary.
- GMP manufacturing facility buildout to complete by Jan 9, 2025; annual revenue capacity $4M-$16M depending on product mix.
- Raised $5.8M net in registered direct offering on Oct 31, 2024; cash ~$10.1M as of Nov 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465924129367/0001104659-24-129367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465924129367/tm2431261d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-129367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer